Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae170 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Dereck Tait und 12 weiteren Autor:innen. Beteiligte Einrichtung: Independent Consultant. Hauptthemen laut MEDLINE: Immunogenicity, Vaccine, Tuberculosis Vaccines, Tuberculosis, Pulmonary. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: IAVI, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
H56:IC31 is a candidate vaccine against tuberculosis (TB) with the potential to reduce TB recurrence rate. It is thus important for future clinical trials to demonstrate safety and immunogenicity of H56:IC31 in individuals treated for TB.
Methods
Twenty-two adults confirmed to be Mycobacterium tuberculosis negative (by 2 GeneXpert tests or 2 sputum cultures) after 4–5 months of TB treatment, and not more than 28 days after completion of TB treatment, were randomized to receive 2 doses of H56:IC31 (5 mg H56:500 nmol IC31; n = 16) or placebo (n = 6) 56 days apart. Participants were followed for 420 days for safety and immunogenicity.
Results
H56:IC31 vaccination was associated with an acceptable safety profile, consisting mostly of mild self-limited injection site reactions. No serious adverse events or vaccine-related severe adverse events were reported. H56:IC31 induced a CD4+ T-cell response for Ag85B and ESAT-6, with ESAT-6 being immunodominant, which persisted through 6 months after the last vaccination. There was some evidence of CD8+ T-cell responses for both Ag85B and ESAT-6, but to a lesser extent than CD4+ responses.
Conclusions
H56:IC31 was associated with an acceptable safety profile, and induced a predominant CD4+ T-cell response, in adults recently treated for drug-susceptible, uncomplicated pulmonary TB. Clinical Trials Registration NCT02375698.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Independent Consultant.
- TASK Clinical Research Centre, Cape Town, South Africa.
- Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.
- IAVI (Formerly Aeras), Cape Town, South Africa.
- Aeras, Rockville, Maryland.
- Novo Nordisk Foundation, Hellerup.
ORCID-Profile: Álvaro H Borges
Förderung
- IAVI
- Bill and Melinda Gates Foundation
Zitieren
APA
Tait, D., Diacon, A., Borges, Á. H., van Brakel, E., Hokey, D., Rutkowski, K. T., Hunt, D. J., Russell, M., Andersen, P. L., Kromann, I., Ruhwald, M., Churchyard, G., & Dawson, R. (2024). Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae170
Vancouver
Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, Rutkowski KT, et al. Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae170
BibTeX
@article{Tait2024,
author = {Tait, Dereck and Diacon, Andreas and Borges, Álvaro H and van Brakel, Elana and Hokey, David and Rutkowski, Kathryn T and Hunt, Devin J and Russell, Marisa and Andersen, Peter L and Kromann, Ingrid and Ruhwald, Morten and Churchyard, Gavin and Dawson, Rodney},
title = {Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae170}
}
EUVIMED